

# ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058  
Dated: 05.02.2018

CIN: U85191DL2011PLG216530

CIN- L85191DL2011PLC216530

The Secretary  
National Stock Exchange of India Ltd  
Exchange Plaza,  
Bandra-Kurla Complex,  
Bandra (E),  
Mumbai – 400051  
Trading Symbol: AGLSL

The Secretary  
BSE Ltd  
PhirozeJeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400001  
Scrip Code:540616

**Sub: Outcome of the Board Meeting held on 05<sup>th</sup> February, 2018**

Dear Sir/ Madam,

We wish to inform you that Board of Directors of the Company in their meeting held on 05.02.2018 have inter alia approved the following:

1. On recommendation of the Audit Committee, the Board of Directors has approved un-audited financial results for the quarter ended 31<sup>st</sup> December, 2017.

Pursuant to Regulation 33 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, we are enclosing the following:

- a. Statement showing the un-audited financial results for the quarter ended 31<sup>st</sup> December, 2017.
  - b. Limited review report with respect to the un-audited financial results for the quarter ended 31<sup>st</sup> December, 2017.
2. The Board of Directors has approved redemption of 11% Non-cumulative redeemable preference shares of Rs. 100/- each in Artemis Health Sciences Limited (wholly owned subsidiary)

The Board Meeting commenced at 1.30 p.m. and concluded at 2:15 p.m.

Please take the above information on your records.

Thanking you  
Yours Faithfully

For Artemis Global Life Sciences Limited

  
Anuj Sood  
Company Secretary (A35276)  
D-6/10, 3rd Floor, Rana Pratap Bagh  
New Delhi-110007

# ANAND DUA & ASSOCIATES

Chartered Accountants

Flat No 11, Pocket-7, Sector-12,  
Dwarka, New Delhi-110 078  
Ph: 47021279

## Limited Review Report

To,  
The Board of Directors,  
Artemis Global Life Sciences Limited

We have reviewed the accompanying statement of unaudited financial results of **Artemis Global Life Sciences Limited** for the quarter and half year ended on 31st December 2017 and unaudited Balance Sheet as on 31st December 2017 attached herewith being submitted by the company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Anand Dua & Associates  
Chartered Accountants  
FRN: 04263N

Place: New Delhi  
Date: 05.02.2018



(Anand Dua)  
Partner  
M.No. 083503

# ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN: U85191DL2011PLC216530

**CIN- L85191DL2011PLC216530**

## STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2017

PART I		RS. LACS					
SL.NO.	PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.03.2017
		(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(AUDITED)
1	Revenue from Operations*	10.20	10.20	10.20	30.60	30.60	40.80
2	Other Income	-	-	-	19.23	-	-
3	<b>Total Income from Operations (I+II)</b>	<b>10.20</b>	<b>10.20</b>	<b>10.20</b>	<b>49.83</b>	<b>30.60</b>	<b>40.80</b>
4	<b>Expenses</b>						
	(a) Employee benefits expense	3.76	3.75	-	11.24	-	-
	(b) Finance Cost	-	-	-	-	-	-
	(c) Depreciation and Amortisation Expense	3.85	3.76	3.67	11.02	11.03	14.71
	(d) Other Expenses	9.99	8.94	0.37	28.92	1.27	4.97
	<b>Total Expenses (IV)</b>	<b>17.60</b>	<b>16.45</b>	<b>4.04</b>	<b>51.18</b>	<b>12.30</b>	<b>19.68</b>
5	<b>Profit / (Loss) from Operations before Exceptional Items and Tax (I-IV)</b>	<b>(7.40)</b>	<b>(6.25)</b>	<b>6.16</b>	<b>(1.35)</b>	<b>18.30</b>	<b>21.12</b>
6	Exceptional Items	-	11.38	-	11.38	-	-
7	<b>Profit/(Loss) from Ordinary Activities before Tax (5-6)</b>	<b>(7.40)</b>	<b>(17.63)</b>	<b>6.16</b>	<b>(12.73)</b>	<b>18.30</b>	<b>21.12</b>
8	Tax Expense	(1.89)	(1.80)	1.57	(0.36)	4.73	6.31
9	<b>Net Profit/(Loss) from Ordinary Activities after Tax (7-8)</b>	<b>(5.51)</b>	<b>(15.83)</b>	<b>4.59</b>	<b>(12.37)</b>	<b>13.57</b>	<b>14.81</b>
10	Extraordinary Items (Net of Tax expenses)	-	-	-	-	-	-
11	<b>Net Profit/(Loss) for the Period (9-10)</b>	<b>(5.51)</b>	<b>(15.83)</b>	<b>4.59</b>	<b>(12.37)</b>	<b>13.57</b>	<b>14.81</b>
12	<b>Other comprehensive income (net of tax)</b>						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	<b>Total Comprehensive income</b>	<b>(5.51)</b>	<b>(15.83)</b>	<b>4.59</b>	<b>(12.37)</b>	<b>13.57</b>	<b>14.81</b>
14	Paid-up Equity Share Capital (Equity Shares of Rs.2/-each)	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77
15	Reserves excluding Revaluation Reserves	**	**	**	**	**	14,568.78
16	<b>EARNINGS PER SHARE (EPS)</b>						
	Basic EPS before & after Extraordinary Items (Not Annualized) -Rs	(0.01)	(0.02)	0.01	(0.02)	0.02	0.02
	Diluted EPS before & after Extraordinary Items (Not Annualized) -Rs	(0.01)	(0.02)	0.01	(0.02)	0.02	0.02

\* Medical Equipment Lease rentals received from Artemis Medicare Services Ltd.

\*\* Not required to be shown

**NOTES:**

- 1 The Company's operation predominantly comprise of only one segment - income from lease of medical equipments to Artemis Medicare Services Ltd. and therefore the figures shown above relate to that segment.
- 2 The scheme of arrangement under sections 391 to 394 of the Companies Act, 1956 read with section 230 to 232 Companies Act, 2013 (the Scheme) between Artemis Global Life Sciences Limited (the Company) and PTL Enterprises Limited (the Demerged Company) and their respective shareholders and the creditors of the two companies for demerger of Medicare and Healthcare Services Business undertaking as a going concern into the Company with the Appointed Date at the opening of business hours on 01st April 2016, has been sanctioned by the Hon'ble High Court of Judicature at Kerala vide its Order dated 16th December, 2016, and the Hon'ble National Company Law Tribunal, New Delhi vide its Order dated 1st March, 2017. Certified copies of the order of the Hon'ble High Court of Judicature at Kerala and Hon'ble National Company Law Tribunal, New Delhi have been filed with the Registrar of Companies at Kerala and Delhi respectively and the scheme has become effective from 8th March 2017. Hence, 5,00,000 Equity Shares of Rs 2 (Indian Rupees Two Only) each fully paid up of the Company were Cancelled, and 6,61,88,500 equity shares of Rs. 2 (Indian Rupees Two Only) each were allotted to the shareholder of the Demerged Company on March 30, 2017 in the ratio of 1 (One) equity share in Company for every 1 (One) equity shares of Rs. 2/- (Indian Rupees Two Only) each held in the Demerged Company. Accordingly the paidup capital of the Company is Rs. 1323.77 Lacs.
- 3 The results incorporate the impact of the above mentioned demerger from the appointed date April 1, 2016. The results for the quarter ended September 30, 2016, quarter ended December 31, 2016 and nine months ended December 31, 2016 have also been restated accordingly to incorporate the impact of demerger.
- 4 The statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under section 133 of the Companies Act 2013, and other recognised accounting practices and the policies to the extent applicable. Being April 1, 2017 company has for the first time adopted Ind AS with the transition date of April 1, 2016.
- 5 The Ind AS compliant corresponding figures for the quarter and nine months ended Dec 31, 2016, have not been subjected to limited review or audit. However the Company management has exercised necessary due diligence to ensure that such financials results provide a true and fair view of its affairs.
- 6 Reconciliation of Profit reported in accordance with previous Indian GAAP (IGAAP) to Total Comprehensive Income in accordance

S.No.	P A R T I C U L A R S	Q U A R T E R E N D E D			N I N E M O N T H E N D I N G	
		31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016
		(Refer Note 2)	(Refer Note 2)	(Refer Note 2)	(Refer Note 2)	(Refer Note 2)
	Profit for the period as per I GAAP	(5.51)	(15.83)	4.59	(12.37)	13.57
	Profit for the period under Ind AS	(5.51)	(15.83)	4.59	(12.37)	13.57
	Other Comprehensive income as per Ind AS	-	-	-	-	-
	<b>Total Comprehensive income as per Ind AS</b>	<b>(5.51)</b>	<b>(15.83)</b>	<b>4.59</b>	<b>(12.37)</b>	<b>13.57</b>

RS. LACS

- 7 Reconciliation of equity as per Previous Indian GAAP (I GAAP) and as per Ind AS is given below

RS. LACS

S.No.	P A R T I C U L A R S	As At	As At
		31.03.2017	01.04.2016
		(Refer Note 2)	(Refer Note 2)
	Equity as per I GAAP	15,883.58	15,868.77
	Equity as per Ind AS	15,883.58	15,868.77

- 8 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 5, 2018. The stand-alone results of the Company have undergone limited review by the Statutory Auditors.

For and on behalf of the Board of Directors of  
ARTEMIS GLOBAL LIFE SCIENCES LIMITED

*Onkar S Kanwar*

ONKAR S KANWAR  
CHAIRMAN

PLACE: GURUGRAM  
DATE: FEBRUARY 5, 2018